Biofil Chemicals Revenue vs. Price To Sales
| BIOFILCHEM | 59.20 0.19 0.32% |
Total Revenue | First Reported 2008-03-31 | Previous Quarter 152 M | Current Value 84.4 M | Quarterly Volatility 49.7 M |
For Biofil Chemicals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biofil Chemicals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biofil Chemicals Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biofil Chemicals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biofil Chemicals Pharmaceuticals over time as well as its relative position and ranking within its peers.
Biofil |
Biofil Chemicals Pha Price To Sales vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Biofil Chemicals's current stock value. Our valuation model uses many indicators to compare Biofil Chemicals value to that of its competitors to determine the firm's financial worth. Biofil Chemicals Pharmaceuticals is the top company in revenue category among its peers. It also is number one stock in price to sales category among its peers . The ratio of Revenue to Price To Sales for Biofil Chemicals Pharmaceuticals is about 190,862,414 . At present, Biofil Chemicals' Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all model that can be used if you cannot value Biofil Chemicals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biofil Chemicals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Biofil Revenue vs. Competition
Biofil Chemicals Pharmaceuticals is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 212.88 Billion. Biofil Chemicals adds roughly 400.35 Million in revenue claiming only tiny portion of equities under Health Care industry.
Biofil Price To Sales vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Biofil Chemicals |
| = | 400.35 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Biofil Chemicals |
| = | 2.10 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Biofil Price To Sales Comparison
Biofil Chemicals is currently under evaluation in price to sales category among its peers.
Biofil Chemicals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Biofil Chemicals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Biofil Chemicals will eventually generate negative long term returns. The profitability progress is the general direction of Biofil Chemicals' change in net profit over the period of time. It can combine multiple indicators of Biofil Chemicals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 320.3 M | 258.5 M | |
| Operating Income | 20.7 M | 21.7 M | |
| Income Before Tax | 8.7 M | 8.6 M | |
| Total Other Income Expense Net | -12 M | -11.4 M | |
| Net Income | 7.1 M | 9.3 M | |
| Income Tax Expense | 1.6 M | 1.9 M | |
| Net Income From Continuing Ops | 7.1 M | 9.1 M | |
| Net Income Applicable To Common Shares | 6.4 M | 9.2 M | |
| Net Interest Income | -415 K | -435.8 K | |
| Interest Income | 488.8 K | 290.8 K | |
| Change To Netincome | 584.2 K | 898.9 K |
Biofil Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Biofil Chemicals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Biofil Chemicals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Biofil Chemicals' important profitability drivers and their relationship over time.
Use Biofil Chemicals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biofil Chemicals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biofil Chemicals will appreciate offsetting losses from the drop in the long position's value.Biofil Chemicals Pair Trading
Biofil Chemicals Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Biofil Chemicals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biofil Chemicals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biofil Chemicals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biofil Chemicals Pharmaceuticals to buy it.
The correlation of Biofil Chemicals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biofil Chemicals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biofil Chemicals Pha moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biofil Chemicals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Biofil Chemicals position
In addition to having Biofil Chemicals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Dividend Yield ETFs Thematic Idea Now
High Dividend Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 107 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Biofil Stock
To fully project Biofil Chemicals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Biofil Chemicals Pha at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Biofil Chemicals' income statement, its balance sheet, and the statement of cash flows.